{"url_path":"/sec/erna/8-k/2026-07-02/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-02","source_url":"https://www.sec.gov/Archives/edgar/data/748592/0001493152-26-031920-index.html","accession_number":"0001493152-26-031920","cik":"0000748592","ticker":"ERNA","issuer_name":"Ernexa Therapeutics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/748592/0001493152-26-031920-index.html","primary_entity_key":"0000748592","primary_entity_name":"Ernexa Therapeutics Inc."},"word_count":303,"has_tables":true,"body_markdown":"**Item\n5.07 Submission of Matters to a Vote of Security Holders.**\n\n** **\n\nOn\nJuly 1, 2027, Ernexa Therapeutics Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”).\n\n \n\nAs\nof the close of business on May 6, 2026, the record date for the Annual Meeting (the “Record Date”), There were 1,166,333\nshares of our common stock issued and outstanding as of the Record Date, all of which are entitled to be voted at the annual meeting.\nAt the Annual Meeting, a total of 619,741 shares of the Company’s common stock, equivalent to approximately 53.13% of the outstanding\nshares, were represented in person or by proxy at the Annual Meeting, constituting a quorum. The final voting results for the proposals\nsubmitted to a vote of the Company’s stockholders at the Annual Meeting are as follows:\n\n \n\nProposal\n1: Each of the director nominees identified below were elected to the Board of Directors of the Company to hold office until the\nCompany’s 2027 Annual Meeting of Stockholders or until their respective successors are elected and qualified, by the votes set\nforth below.\n\n \n\n \n \nVotes\n \nVotes\n \nBroker\n\nDirector\n \nFor\n \nWithheld\n \nNon-Votes\n\nJames\nBristol\n \n455,380\n \n3,196\n \n161,165\n\nPeter\nCicala\n \n455,121\n \n3,455\n \n161,165\n\nSanjeev\nLuther\n \n442,564\n \n16,012\n \n161,165\n\nElena\nRatner\n \n455,633\n \n2,943\n \n161,165\n\nWilliam\nWexler\n \n455,156\n \n3,420\n \n161,165\n\n \n\nProposal\n2: The Company’s stockholders ratified, by the votes set forth below, the appointment of Haskell & White LLP as the Company’s\nindependent registered public accounting firm for the 2026 fiscal year.\n\n \n\nVotes\n \nVotes\n \n \n \nBroker\n\nFor\n \nAgainst\n \nAbstentions\n \nNon-Votes\n\n590,236\n \n29,010\n \n495\n \n—\n\n \n\nProposal\n3: The Company’s stockholders approved the adoption of the 2026 Ernexa Therapeutics Inc. Omnibus Equity Incentive Plan by the\nvotes set forth below.\n\n \n\nVotes\n \nVotes\n \n \n \nBroker\n\nFor\n \nAgainst\n \nAbstentions\n \nNon-Votes\n\n363,640\n \n94,840\n \n96\n \n161,165\n\n \n\nNo\nother matters were considered or voted upon at the Annual Meeting."}